|
|
||||||||
Papers In Press, published online ahead of print August 29, 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cell Biology & Genetics, Erasmus University Medical Center, Rotterdam 3015 GD
Corresponding Author: m.decrom{at}erasmusmc.nl
In low-density lipoprotein receptor (LDLR) deficient mice, overexpression of human plasma phospholipid transfer protein (hPLTP) results in increased atherosclerosis. PLTP strongly decreases high-density lipoprotein (HDL) levels, and might alter the anti-atherogenic properties of HDL particles. To study the potential interaction between human PLTP and apolipoprotein AI, double transgenic animals (hPLTPtg/hApoAItg) were compared with hApoAItg mice. PLTP activity was 4.5-fold increased. Total plasma TC and PL were decreased. Average HDL size (analyzed by gel filtration) increased strongly, hPLTPtg/hApoAItg mice having very large, LDL-sized, HDL particles. Also after density gradient ultracentrifugation, a substantial part of the ApoAI containing lipoproteins in hPLTPtg/hApoAItg mice was found in the LDL density range. In cholesterol efflux studies from macrophages, HDL isolated from hPLTPtg/hApoAItg mice was less efficient than HDL isolated from hApoAItg mice. Furthermore, it was found that the largest subfraction of the HDL particles present in hPLTPtg/hApoAItg mice was markedly inferior as cholesterol acceptor, as no labeled cholesterol was transferred to this fraction. In an LDLR deficient background, the hPLTP expressing mouse line showed a 2.2-fold increased atherosclerotic lesion area. These data demonstrate that the action of hPLTP in presence of hApoAI results in the formation of a dysfunctional HDL subfraction, which is less efficient in the uptake of cholesterol from cholesterol-laden macrophages.
Revised on August 28, 2007
Accepted on August 28, 2007
Atherogenic, enlarged and dysfunctional HDL in human PLTP/ApoAI double transgenic mice
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
W. A. van der Steeg, I. Holme, S. M. Boekholdt, M. L. Larsen, C. Lindahl, E. S.G. Stroes, M. J. Tikkanen, N. J. Wareham, O. Faergeman, A. G. Olsson, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J. Am. Coll. Cardiol., February 12, 2008; 51(6): 634 - 642. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |